Adverum Biotechnologies
800 Saginaw Drive
Redwood City, CA 94063
United States
182 articles about Adverum Biotechnologies
-
Adverum Biotechnologies Announces New Executive Leadership Roles
5/25/2023
Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced new executive leadership roles that support the ongoing development of the investigational gene therapy ixoberogene soroparvovec.
-
Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting
5/18/2023
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced new nonclinical data supporting the use of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting in Los Angeles, California.
-
Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform
5/18/2023
Adverum Biotechnologies, Inc. presented new nonclinical data on an IVT gene therapy for the treatment of GA secondary to dry age-related macular degeneration via expression of CFI at the American Society of Gene & Cell Therapy 2023 Annual Meeting, in Los Angeles, California.
-
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
5/11/2023
Adverum Biotechnologies, Inc. reported financial results for the first quarter ended March 31, 2023 and provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec for the treatment of wet age-related macular degeneration.
-
Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference
5/10/2023
Adverum Biotechnologies, Inc. announced that members of the executive team will participate in a fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference being held on Wednesday, May 17, 2023 at 3:35 p.m. ET in New York, New York.
-
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD
5/2/2023
Adverum Biotechnologies, Inc. announced new data will be presented during the American Society of Gene & Cell Therapy 2023 Annual Meeting being held May 16-20, 2023, in Los Angeles, California.
-
Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec
4/23/2023
Adverum Biotechnologies, Inc. announced nonclinical data supporting the two doses of ixoberogene soroparvovec being evaluated in the Phase 2 LUNA trial and the potential for staggered, bilateral administration in the treatment of wet AMD.
-
Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD
4/18/2023
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Ixo-vec (ixoberogene soroparvovec), an investigational gene therapy for the treatment of wet AMD, an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP).
-
Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting
4/17/2023
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the company will present an abstract featuring nonclinical data of Ixoberogene soroparvovec (Ixo-vec) for the treatment of neovascular age-related macular degeneration at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting.
-
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
3/30/2023
Adverum Biotechnologies, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related macular degeneration (wet AMD).
-
Adverum Biotechnologies to Present at Upcoming March 2023 Investor Conferences
2/27/2023
Adverum Biotechnologies, Inc. announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the following upcoming investor conferences:
-
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 18, 2023
1/18/2023
Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee.
-
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 06, 2022
12/6/2022
Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee.
-
Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
11/10/2022
Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced financial results for the third quarter ended September 30, 2022.
-
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
11/4/2022
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced long-term follow-up data from the OPTIC study treating wet age-related macular degeneration (wet AMD) during The Retina Society Annual Meeting in Pasadena, California.
-
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
10/27/2022
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that new data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week at The Retina Society Annual Meeting in Pasadena, California.
-
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
9/30/2022
Adverum Biotechnologies, Inc. announced new analyses from the OPTIC study treating wet age-related macular degeneration during the Late Breaking Developments portion of Retinal Subspecialty Day at the American Academy of Ophthalmology 2022 Annual Meeting in Chicago, Illinois.
-
Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference
9/27/2022
Adverum Biotechnologies, Inc. today announced that Richard Beckman, M.D., chief medical officer of Adverum Biotechnologies, will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET.
-
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
9/23/2022
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Peter Soparkar, chief operating officer of Adverum Biotechnologies, will present at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET.
-
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
9/23/2022
Adverum Biotechnologies, Inc. today announced that data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week during the Late Breaking Developments portion of Retinal Subspecialty Day.